Sagimet Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021
Net Income	-27.88	-30.5	-24.44
Depreciation & Amortization	0.14	0.13	0.13
Share-Based Compensation	4.99	1.88	1.9
Other Operating Activities	-1.02	4	0.69
Operating Cash Flow	-23.77	-24.49	-21.71
Change in Investments	12.58	-32.01	0
Investing Cash Flow	12.58	-32.01	0
Share Issuance / Repurchase	89.69	0.01	0.19
Debt Issued / Paid	-3.52	-0.09	-1.25
Other Financing Activities	-	-	10.8
Financing Cash Flow	86.17	-0.07	9.74
Net Cash Flow	74.98	-56.57	-11.97
Free Cash Flow	-23.77	-24.49	-21.71
Free Cash Flow Margin	-1188.30%	-	-
Free Cash Flow Per Share	-2.27	-132.65	-2.23

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).